Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

NCT02281760 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

NIH

Sponsor class

Conditions

BRAF V600E Mutation

Interventions

DRUG: Dabrafenib Mesylate
DRUG: Trametinib Dimethyl Sulfoxide

Sponsor

National Human Genome Research Institute (NHGRI)